RxDoctor Payments Data

Heather Pryor, MD

Family Medicine · Cedartown, GANPI 1588697635

Payments from drug & device makers

$8,854in general payments, 2019–2025

Across 596 payments — averaging $14.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$968
  • Lilly USA, LLC$678
  • Pfizer$673
  • GSK$575
  • Astellas Pharma US Inc$487
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$8,828100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,854 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$132,311
Medicare patients
238
Services billed
17,795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide146$182,701
JardianceEmpagliflozin107$103,581
OzempicSemaglutide62$98,066
FarxigaDapagliflozin Propanediol70$73,004
EliquisApixaban75$70,226
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$64,592
MyrbetriqMirabegron71$51,220
TrulicityDulaglutide35$37,078
Repatha SureclickEvolocumab23$30,283
ProliaDenosumab14$23,782
TradjentaLinagliptin19$23,719
RybelsusSemaglutide18$22,552
LinzessLinaclotide12$21,481
JanuviaSitagliptin Phosphate17$21,052
VraylarCariprazine Hcl12$18,400

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$678$219,779181 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$221$132,922137 claims
Novo NordiskOzempic, Rybelsus$968$120,61980 claims
GSKTrelegy Ellipta, Breo Ellipta$575$78,72473 claims
AstraZenecaFarxiga$369$73,00470 claims
PfizerEliquis$673$70,22675 claims
Astellas Pharma US IncMyrbetriq$487$51,22071 claims
AbbVieLinzess, Vraylar, Synthroid$1,759$43,02254 claims
MerckJanuvia, Belsomra$26$26,20429 claims
AmgenProlia$401$23,78214 claims
Johnson & JohnsonXarelto$110$18,32326 claims
Sumitomo Pharma America, Inc.Gemtesa$125$9,78012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Cedartown

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →